Can a Simple Skin Cream Ease Nerve Pain?
"A single-blind study explores the potential of topical phenytoin for neuropathic pain relief, offering a promising alternative for those seeking localized treatment."
Living with localized neuropathic pain can feel like an endless search for relief. Existing treatments often come with a host of side effects, leaving many seeking gentler, more targeted options. That's where topical analgesics, like creams containing active compounds such as phenytoin, offer a glimmer of hope.
Phenytoin, traditionally used to manage seizures, has shown promise in easing neuropathic pain when applied directly to the skin. Compounded analgesic creams are developed by local pharmacists and have the ability to contain high concentrations of active compounds for topical and local use, while minimizing what reaches the blood stream. But how effective is it really, and can it offer a breakthrough for those struggling with persistent nerve pain?
Researchers have been exploring this very question. One recent study delved into the potential of a 10% phenytoin cream to alleviate neuropathic pain. The goal was to evaluate a single-blind placebo-controlled response test (SIBRET) for use in clinical practice. Let's break down the findings and explore what this could mean for the future of pain management.
A Growing Class of Topical Analgesics
Since 2000, topical analgesics have drawn increasing interest for the treatment of peripheral neuropathic pain, in large part because they offer advantages over oral medication: no systemic side effects and drug-drug interactions, fast onset of pain relief, and a high concentration of the active compound at the application area. Clinical evaluation has begun to follow, with a retrospective study in patients with painful diabetic neuropathy (PDN) assessing the analgesic effect of topical phenytoin cream in response tests and after extended use. Efficacy and safety are also under investigation in a registered trial (NCT04647877) enrolling patients with neuropathic pain due to chronic idiopathic axonal polyneuropathy (CIAP). A parallel line of work has explored identifying responders through a single-blind placebo-controlled response test, and the researchers behind that approach hold patents covering topical phenytoin for peripheral neuropathic pain.
Standard Care Has Real Drawbacks
Conventional neuropathic pain management commonly centers on systemic medications, but such oral options come with well-known limitations, including systemic side effects and the risk of drug-drug interactions. By contrast, local, topically applied treatments have attracted attention because they confine the active compound to the area where pain is felt. However, the evidence supporting topical products varies widely by formulation and pain condition, so prescribing decisions still tend to rest on trial-and-error rather than on settled comparative data. Research into topical phenytoin cream is at an early stage, and its role relative to accepted standard care remains to be confirmed.
From 1908 Synthesis to Modern Repurposing
Phenytoin, a barbiturate derivative synthesized in 1908, was first explored for medical use in the late 1930s, and its history is widely considered an important hallmark of drug discovery and development. More than 80 years on, the molecule is being repurposed—as an old drug in a new indication, specifically a topical formulation for peripheral neuropathic pain. Its most established mechanism is sodium-channel blockade, though phenytoin also appears to carry an anti-inflammatory action, relevant because mild neuro-inflammatory conditions may play a pathogenic role in various forms of peripheral neuropathic pain. Researchers in the field note that many pharmacological studies tested only a single dose, mostly 50 or 100 μM, which most probably exceeds the non-protein-bound phenytoin plasma levels reached during clinical treatment.
The Phenytoin Cream Study: A Closer Look
The study focused on individuals experiencing localized neuropathic pain with similar intensity in at least two areas of the body. Participants underwent a single-blind test where one area received a placebo cream (the base cream without phenytoin) and the other received the 10% phenytoin cream. To avoid bias, the creams were applied with separate hands.
- A total of 21 patients participated in the study.
- An impressive 15 patients (71.45%) were classified as responders.
- On average, pain reduction in the phenytoin cream area was 3.3 (SD: 1.3) on the NRS, compared to 1.2 (SD: 1.1) in the placebo area.
- The difference in mean percentage pain reduction between the phenytoin and placebo creams was a significant 33.2% (SD: 17.6, p < 0.001).
- Using a stricter criterion of 50% pain reduction, researchers identified 57.1% responders on phenytoin cream versus only 9.5% on placebo.
Response Tests, Open-Label Data, and a Scoping Review
A retrospective study published in early 2025 evaluated topical phenytoin cream in patients with painful diabetic neuropathy, testing its analgesic effect both in response tests and after extended use, and framed the cream as a promising innovative approach to unmet needs in neuropathic pain treatment. That promise is echoed by a scoping review examining case reports, case series, and pre-existing research articles, which found that topical phenytoin significantly reduces neuropathic pain and concluded it may be an alternative in therapy selection because of its minimal side effects compared with oral therapy. Meanwhile, a trial listed in a clinical registry is evaluating phenytoin cream in neuropathic pain due to chronic idiopathic axonal polyneuropathy (CIAP), with a second objective of determining whether a double-blind placebo-controlled response test (DOBRET) can predict sustained responders.
Not Every Patient Responds
The evidence base for topical analgesics in neuropathic pain is being assembled through structured expert review, with one panel searching PubMed and reference lists of published articles to evaluate efficacy and safety and to offer treatment guidance rather than relying on any single trial. Case-level evidence is candid about limitation: in a collection of phenytoin cream cases, the authors stressed that the cream's fast onset of action enables clinicians to differentiate responders from non-responders via a single-blind response test that applies both placebo and active creams to two different localized pain areas. This built-in responder screening implies that a meaningful share of patients will not benefit, and the field's heavy reliance on case series underscores the need for controlled data before efficacy claims can be considered settled.
Head-to-Head Evidence Still Emerging
Because topical phenytoin cream is still in the early stages of clinical evaluation, robust head-to-head comparisons against established oral therapies for neuropathic pain do not yet exist. Published reports highlight general advantages of topical delivery, such as rapid onset of relief and minimal systemic exposure, but these are characteristics of the route rather than proven superiority over any specific comparator. Until controlled trials and responder-test data accumulate, the comparative performance of phenytoin cream relative to accepted treatments should be viewed as an open question rather than a settled conclusion.
A Step Towards Personalized Pain Management
The study's conclusion highlights the potential of the SIBRET test as a valuable tool for identifying individuals who are likely to benefit from phenytoin cream. This approach aligns with the growing trend of personalized medicine, where treatments are tailored to individual patient characteristics and responses.
Promising but Not Yet Proven
Taken together, the available evidence suggests topical phenytoin cream may address real gaps in neuropathic pain care, particularly for patients who do not tolerate systemic medications or who fail to respond to them. The recurring emphasis on fast responder testing, minimal systemic exposure, and low side-effect burden points to clinical strengths that oral treatments often lack. At the same time, much of this evidence derives from case series and retrospective or open-label work, so independent controlled trials will be needed to substantiate the claims. The most measured takeaway is guarded optimism: promising signal, pending proof.
Market Growth and Next-Generation Pain Care
Commercial projections are markedly bullish for this segment: the global non-opioid topical pain relief market is expected to grow from around USD 5 billion in 2025 to roughly USD 12 billion by 2035, a CAGR of 8.2% over the forecast period. Analysts similarly describe the US neuropathic pain market as experiencing transformative growth driven by innovative treatment approaches and demographic shifts. Looking further out, AI-driven diagnostics, wearable devices, gene therapy, and advanced neuromodulation systems are expected to transform the neuropathic pain market. Topical phenytoin cream sits squarely within the expanding non-opioid topical segment even as these broader innovations reshape how nerve pain is diagnosed and managed.
Local Relief Without Systemic Exposure
Whole-body drug exposure is a central challenge in neuropathic pain treatment, and topical phenytoin has been characterized on exactly that question: in reported patients, plasma levels of phenytoin remained under the limit of detection, considerably reducing risks related to systemic exposure. In several case series, phenytoin 5% and 10% cream reduced pain in a clinically relevant way with a fast onset of action within 30 minutes. Investigators have also described quick and long-lasting analgesic effects in patients with various painful neuropathic syndromes treated with phenytoin 10% cream. Together these observations illustrate the broader systemic tension in the field—maximizing local efficacy while keeping systemic side effects and drug interactions to a minimum.
Help for Patients Other Drugs Left Behind
The human stories behind phenytoin cream center on patients who had run out of options. In developing a new cream based on 5% and 10% phenytoin, researchers described three successfully treated patients suffering from neuropathic pain, all of whom were refractory to a number of other analgesics. A related case series reported that the phenytoin cream reduced neuropathic pain considerably, with a fast onset of analgesic effect. Still other case reports document the safety and efficacy of the cream in individual patients with neuropathic pain, some of whom were identified as responders through a fast responder test. For these individuals, an easy-to-administer topical cream with a low propensity for inducing side effects can represent a meaningful alternative where standard analgesics have failed.
Furthermore, the findings offer compelling evidence for the analgesic activity of 10% phenytoin cream, suggesting it could be a viable option for those seeking localized pain relief. The fact that pain reduction occurred rapidly, without significant absorption into the bloodstream, points to a direct effect on peripheral nerves.
While more research is needed to optimize the use of phenytoin cream and identify the ideal candidates, this study provides a promising step forward in the quest to conquer neuropathic pain.